Related Experiment Video
Updated: Jul 13, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
A Human Pharmacogenomics Approach Provides Insight Into the Pathogenesis and Pathophysiology of Steroid-Induced
Zeyuan Song1,2, Satyabrata Pany3, Shengru Guo4
1Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts.
Purpose:
To identify single nucleotide polymorphisms (SNPs) and their likely target genes associated with steroid-induced ocular hypertension (SI-OHT), and to conduct functional annotation analyses.
Design:
Genome-wide association study (GWAS).
Participants:
Patients with Fuchs endothelial corneal dystrophy were enrolled after corneal transplantation at a single clinical practice (N = 439). Patients self-administered 1% prednisolone acetate eyedrops after surgery. Intraocular pressure (IOP) was measured at baseline and at 1, 3, 6, and 12 months postsurgery.
Methods:
Saliva samples were collected, and DNA was extracted and genotyped. A GWAS was then conducted, with maximum change in IOP serving as the quantitative trait (QT). Replication analysis employed 4 independent cohorts (N = 49-103) with participants that had been previously genotyped.
Main Outcome Measures:
Linear regression analysis was performed to determine association between QT and genotype using the Haplotype Reference Consortium reference panel for imputation.
Results:
A total of 46 SNPs of genome-wide significance (P < 5E-08) clustered at 29 different risk loci in a total of 623 SNPs of suggestive significance (P < 5E-06) clustered at 323 risk loci. Most SNPs are rare or of low frequency with large effect sizes. A list of 441 prioritized target genes was validated by comparison to gene profiling study results and by annotation analyses. Of the top 29 risk loci, 31% colocalize with those for other high-tension OHT phenotypes, and 2 more are linked to OHT by biological evidence for a total of 38% overlap. Three of the discovered SNPs were independently replicated. Many of the prioritized target genes are not expressed in trabecular meshwork or juxtacanalicular tissue, contrary to the current disease paradigm. Annotation analyses suggest novel pathophysiologic mechanisms.
Conclusions:
Why some individuals develop SI-OHT, but others do not, has remained unknown since glucocorticoids were first used to treat eye disease in the early 1950s. Results of this study demonstrate a genetic basis for SI-OHT, support a relationship with other high-tension OHT phenotypes, and provide hypothesis-generating information for laboratory follow-up. Discovered and replicated SNPs may be valuable for SI-OHT risk prediction and prioritized target genes might be targeted for SI-OHT management.
Financial Disclosures:
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Ophthalmic Drug Delivery Systems

